Auto1 Group Se AUTO1 GROUP ORD SH.../ DE000A2LQ884 /
5/24/2024 6:36:51 PM | Chg. - | Volume | Bid6:00:04 AM | Ask6:00:04 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
6.624EUR | - | 3,105 Turnover: 20,485.466 |
-Bid Size: - | -Ask Size: - | 1.21 bill.EUR | - | - |
GlobeNewswire
5/31
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 ...
GlobeNewswire
5/31
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clon...
GlobeNewswire
5/17
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
5/14
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in ...
GlobeNewswire
4/24
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of ob...
GlobeNewswire
4/2
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the Europe...
GlobeNewswire
3/14
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
GlobeNewswire
3/12
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certificati...
GlobeNewswire
2/8
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
2/8
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
1/22
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleuc...
GlobeNewswire
12/10/2023
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annu...
GlobeNewswire
11/27/2023
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for ...
GlobeNewswire
11/15/2023
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) An...
GlobeNewswire
11/2/2023
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) An...
GlobeNewswire
11/2/2023
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
GlobeNewswire
9/5/2023
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia pu...
GlobeNewswire
3/10/2022
Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Pro...
GlobeNewswire
11/4/2021
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
GlobeNewswire
11/3/2021
Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
GlobeNewswire
9/9/2021
Flo Announces $50 Million Series B Funding Round; Bringing Company to $800M Valuation
GlobeNewswire
9/1/2021
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with r...
GlobeNewswire
8/9/2021
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the t...
GlobeNewswire
8/5/2021
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress